(NASDAQ: AMRN) Amarin's forecast annual revenue growth rate of -11.38% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.26%.
Amarin's revenue in 2024 is $264,779,000.On average, 3 Wall Street analysts forecast AMRN's revenue for 2024 to be $81,883,084,063, with the lowest AMRN revenue forecast at $79,915,219,078, and the highest AMRN revenue forecast at $85,433,135,521. On average, 3 Wall Street analysts forecast AMRN's revenue for 2025 to be $70,373,170,873, with the lowest AMRN revenue forecast at $63,813,757,979, and the highest AMRN revenue forecast at $80,355,172,177.
In 2026, AMRN is forecast to generate $79,152,907,819 in revenue, with the lowest revenue forecast at $73,435,162,211 and the highest revenue forecast at $89,405,048,550.